Key result
Morning vs. evening antihypertensive dosing shows no benefit for mortality or major cardiovascular events.
Why the study?
The relationship between the timing of antihypertensive medication administration and cardiovascular outcomes is not well established, with prior studies yielding conflicting results.
Does morning versus evening administration of antihypertensive medication alter the risk of all-cause mortality, major adverse cardiovascular events, or stroke in patients with hypertension?
Meta-Analysis (n=46,857)
Does morning versus evening administration of antihypertensive medication alter the risk of all-cause mortality, major adverse cardiovascular events, or stroke in patients with hypertension?
This meta-analysis of 6 RCTs (n=46,857) confirms that the timing of antihypertensive medication administration (morning vs. evening) does not significantly affect all-cause mortality, MACE, or stroke.
Answers are grounded in this paper and cite their sources.
Antihypertensive dosing time can be individualized for convenience; confirms BEDMED trial and strengthens evidence for flexible regimens.
Hypertension significantly contributes to the risk of cardiovascular disease and associated mortality. The timing of medication use and associated cardiovascular outcomes is not well established, with conflicting results. We evaluated the association between morning versus evening antihypertensive medication and cardiovascular outcomes. We performed a systematic literature search on PubMed, Scopus, and ClinicalTrial.gov for relevant randomized controlled trials (RCTs) from inception until June 5, 2026. Studies were considered eligible for inclusion if patients with hypertension received antihypertensive medication in the intervention group during the morning/daytime and in the control group in the evening. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using a random-effect model, and a P value of <0.05 was considered statistically significant. Six RCTs with 46,857 patients (23,488 assigned to morning antihypertensive medication and 23,369 assigned to evening antihypertensive medication) were included in the analysis. The mean age of patients was 63.3 years. Pooled analysis demonstrated no statistically significant difference between morning and evening antihypertensive medication dosing for all-cause mortality (OR 1.30, 95% CI 0.92-1.85, P = 0.14), major adverse cardiovascular events (OR 1.28, 95% CI 0.93-1.76, P = 0.13), or stroke (OR 1.45, 95% CI 0.96-2.19, P = 0.08). This meta-analysis supports the findings of the BEDMED 2025 trial, with no significant differences between morning and evening administration of antihypertensive drugs and cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
Jaiswal et al. (2026) conducted a meta-analysis in Hypertension (n=46,857). Morning/daytime antihypertensive medication dosing vs. Evening antihypertensive medication dosing was evaluated on All-cause mortality (OR 1.30, 95% CI 0.92-1.85, p=0.14). Morning versus evening antihypertensive dosing showed no significant difference in all-cause mortality or major cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: